Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.

[1]  A. Jakubowska,et al.  Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland , 2015, Clinical genetics.

[2]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[3]  T. Dörk,et al.  Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe , 2014, Familial Cancer.

[4]  Tina Pesaran,et al.  Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients , 2014, Genetics in Medicine.

[5]  P. Dundr,et al.  The PALB2 Gene Is a Strong Candidate for Clinical Testing in BRCA1- and BRCA2-Negative Hereditary Breast Cancer , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  Daniel J. Park,et al.  Tumour morphology predicts PALB2 germline mutation status , 2013, British Journal of Cancer.

[7]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[8]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[9]  Daniel J. Park,et al.  A PALB2 mutation associated with high risk of breast cancer , 2010, Breast Cancer Research.

[10]  Bing Xia,et al.  PALB2/FANCN: recombining cancer and Fanconi anemia. , 2010, Cancer research.

[11]  S. Hammes,et al.  Just when you thought it was safe to go into the membrane: the growing complexities of extra-nuclear progesterone signaling , 2010, Breast Cancer Research.

[12]  F. Sera,et al.  A PALB2 germline mutation associated with hereditary breast cancer in Italy , 2010, Familial Cancer.

[13]  M. Dąbrowska,et al.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.

[14]  H. Nevanlinna,et al.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.

[15]  P. Pharoah,et al.  Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? , 2009, British Journal of Cancer.

[16]  J. Hopper,et al.  Penetrance Analysis of the PALB2 c.1592delT Founder Mutation , 2008, Clinical Cancer Research.

[17]  W. Foulkes,et al.  Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.

[18]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[19]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[20]  J. Lubiński,et al.  Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland , 2006, Hereditary Cancer in Clinical Practice.

[21]  A. Jakubowska,et al.  Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. , 2000, American journal of human genetics.

[22]  Karla Bowles,et al.  Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel , 2015, Cancer.